News

Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.

A recent retrospective cohort study found that among patients with newly diagnosed ovarian cancer, real-world patterns of upfront bevacizumab use prior to FDA approval in 2018 differed significantly from trial data.

A recent health care claims databases analysis revealed that among patients with MM, the mean, total, all-cause health care cost during 21 months of follow-up was found to be nearly $723,000.

The American Society of Clinical Oncology (ASCO) recently created the ASCO Center for Equity, Diversity, and Inclusion, which is designed to promote equity, diversity, and inclusion (EDI) goals across the organization and throughout the wider...

An analysis of internal processes by physicians in a radiation oncology practice at Vanderbilt University Medical Center determined that the time and cost burdens of treatment-related prior authorizations for such practices are substantial...

Black patients reported significantly greater general pain both before the initiation of radiation therapy and at the end of radiation therapy, according to an analysis of racial differences in thoracic radiation treatment and related...

Findings from a retrospective cohort study suggest that patients with metastatic, castration-resistant prostate cancer experience higher costs, and require more outpatient services, compared with those with nonmetastatic cancer.

Study findings suggest margetuximab plus chemotherapy is not cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast cancer.

Greater reliance on genomic assays has reduced the use of adjuvant chemotherapy in women with early-stage, HR–positive, HER2–negative breast cancer who are free of axillary node disease and at low genomic risk, according to a recent study.

Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.